Based on up-to-date knowledge, the hypothesis behind our study is that intranasal administration of CRHR2 agonists (Ucn2 and Ucn3) may potentially prevent the development of PTSD-like manifestations at the behavioral and molecular levels. Here, CRHR2 is linked to post-traumatic stress disorder.